Serum levels of IGF-I and IGF-II in patients with lung cancer during chemotherapy.
The AIM of this study was to assess the influence of chemotherapy on the serum levels of IGF-I and IGF-II in patients with lung cancer.


METHODS
The study included 38 patients (33 males and 5 females) at mean age of 59.8, diagnosed histologically with lung cancer. Twenty five patients had non-small cell lung cancer (NSCLC) including 11 patients with squamous cell carcinoma (SCC), 5 patients with adenocarcinoma and 9 patients without an essential histological type of NSCLC. A total of 13 patients had small cell lung cancer (SCLC). The control group consisted of 10 healthy volunteers. The peripheral blood samples were taken before and after 4 cycles of chemotherapy. IGF-I and IGF-II levels were assessed by ELISA method.


RESULTS
Serum levels of IGF-I and IGF-II measured before chemotherapy were significantly higher in both NSCLC and SCLC groups in comparison with controls. There were no significant differences of serum levels of both growth factors before and after 4 cycles of chemotherapy. Serum levels of IGF-I and IGF-II were still high after chemotherapy in patients with NSCLC and SCLC. Patients with SCC and adenocarcinoma had similar serum levels of IGF-I and IGF-II without statistical differences.


CONCLUSIONS
Serum levels of IGF-I and IGF-II were significantly higher in patients with NSCLC and SCLC before chemotherapy than in controls. Chemotherapy had no influence on the serum levels of insulin-like growth factors (IGFs). Serum levels of IGF-I and IGF-II did not depend on a histological type of NSCLC either.
Izycki
T
T
Department of Lung Diseases and Tuberculosis, Medical University of Bialystok, Poland. tomekiz@mp.pl
Chyczewska
E
E
Naumnik
W
W
Talalaj
J
J
Panek
B
B
Ossolinska
M
M
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000097:blood*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000473:pathology*; D018288:Carcinoma, Small Cell / Q000188:drug therapy* / Q000473:pathology*; D023381:Endpoint Determination; D005260:Female; D006801:Humans; D007334:Insulin-Like Growth Factor I / Q000032:analysis*; D007335:Insulin-Like Growth Factor II / Q000032:analysis*; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D016896:Treatment Outcome
D014408:Biomarkers, Tumor; D007334:Insulin-Like Growth Factor I; D007335:Insulin-Like Growth Factor II